登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
BEX101 in B-cell Non-Hodgkin's Lymphoma
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由中国人民解放军总医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07882641,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 5
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(5 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Subjects who are fertile, and/or whose partners are of childbearing potential, must agree to use effective contraception throughout the treatment period and for 24 months after completion of treatment, and must not donate ova or sperm for assisted reproduction during this period. Women of childbearing potential (women who have undergone sterilization or have been postmenopausal for ≥ 12 months are not considered to be of childbearing potential) must have a negative urine or serum pregnancy test during screening.
入选标准第 8 条
History of or concurrent active malignancy. Exceptions include curatively treated carcinoma in situ of the cervix, noninvasive basal cell or squamous cell skin cancer, locally confined prostate cancer after definitive treatment, or ductal carcinoma in situ after curative surgery, provided there has been no recurrence for at least 3 years;
排除标准第 2 条
Prior allogeneic stem cell transplantation, or autologous stem cell transplantation within 3 months prior to planned infusion of BEX101 injection.
排除标准第 3 条
Prior antitumor therapy for which the washout period has not exceeded 5 half-lives before the planned infusion of BEX101 injection.
排除标准第 9 条
Participation in another interventional clinical study within 3 months prior to signing the informed consent form, receipt of active investigational drug treatment, or intention to participate in another clinical trial or receive treatment for autoimmune disease outside the protocol during the study period.
排除标准第 17 条
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.
入选标准第 6 条
At least one measurable target lesion, defined as: longest diameter of an intra-nodal lesion > 1.5 cm; or longest diameter of an extra-nodal lesion > 1.0 cm (according to the 2014 Lugano Classification response criteria).
入选标准第 3 条
Pregnant or breastfeeding women.
排除标准第 15 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07882641,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Age 18 to 75 years (inclusive), regardless of sex. Subjects who meet the following diagnostic and treatment requirements: At least one measurable target lesion, defined as: longest diameter of an intra-nodal lesion > 1.5 cm; or longest diameter of an extra-nodal lesion > 1.0 cm (according to the 2014 Lugano Classification response criteria). CD19-positive tumor tissue confirmed by histopathology. A prior CD19 pathology diagnosis may be accepted if confirmed by the investigator. Subjects previously treated with anti-CD19 therapy must undergo tumor biopsy to confirm current CD19-positive expression. Any toxicities from prior therapies must be stable and recovered to Grade ≤ 1 (except for hematologic toxicities and clinically insignificant toxicities such as alopecia). Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1. Organ function must meet the following criteria: Subjects who are fertile, and/or whose partners are of childbearing potential, must agree to use effective contraception throughout the treatment period and for 24 months after completion of treatment, and must not donate ova or sperm for assisted reproduction during this period. Women of childbearing potential (women who have undergone sterilization or have been postmenopausal for ≥ 12 months are not considered to be of childbearing potential) must have a negative urine or serum pregnancy test during screening. Willing to comply with all study procedures, voluntarily participate in the study, and sign the informed consent form.排除标准:Exclusion Criteria:
Estimated life expectancy < 3 months. History of or concurrent active malignancy. Exceptions include curatively treated carcinoma in situ of the cervix, noninvasive basal cell or squamous cell skin cancer, locally confined prostate cancer after definitive treatment, or ductal carcinoma in situ after curative surgery, provided there has been no recurrence for at least 3 years; Prior allogeneic stem cell transplantation, or autologous stem cell transplantation within 3 months prior to planned infusion of BEX101 injection. History of central nervous system (CNS) disease or presence of clinically significant CNS dysfunction, such as cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, epilepsy, aphasia, or other similar conditions. Myocardial infarction, cardiac angioplasty or stent implantation, unstable angina, or other clinically significant cardiac disease within 12 months prior to screening. Lymphoma involvement of the atrium or ventricle. Presence of CNS metastases or symptoms suggestive of CNS metastases. Ongoing or anticipated tumor-related emergency requiring treatment within 6 weeks after signing the informed consent form, such as mass effect from tumor bulk or tumor lysis syndrome. Prior antitumor therapy for which the washout period has not exceeded 5 half-lives before the planned infusion of BEX101 injection. Use of any of the following drugs or treatments within the specified time periods. Uncontrolled active bacterial, fungal, or viral infection, or any other infection that, in the investigator's judgment, makes the subject unsuitable for study participation. Positive for HIV antibody, positive for Treponema pallidum antibody, positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) with detectable peripheral blood HBV DNA, or positive for hepatitis C virus (HCV) antibody with detectable HCV RNA; exceptions may be made for infections considered preventable or controllable with medication in the investigator's judgment. Known active autoimmune disease requiring systemic treatment. Known severe hypersensitivity to any study medication or any of its components. Pregnant or breastfeeding women. Receipt of a live vaccine within 6 weeks prior to enrollment. Participation in another interventional clinical study within 3 months prior to signing the informed consent form, receipt of active investigational drug treatment, or intention to participate in another clinical trial or receive treatment for autoimmune disease outside the protocol during the study period. Patients with psychiatric disorders such as depression or suicidal ideation/tendency. Any other medical condition that may affect the safety or efficacy evaluation of the investigational product. Any other factor that, in the investigator's judgment, renders the subject unsuitable for enrollment or may interfere with the subject's participation in or completion of the study.
引自 ClinicalTrials.gov, NCT07882641, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07882641,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。